Apr 10 2012
Akorn, Inc. (NASDAQ: AKRX), a niche specialty pharmaceutical company,
today announced that it has launched Vancomycin Hydrochloride USP 125mg
and 250mg capsules, the generic version of ViroPharma's Vancocin®, which
is indicated for the treatment of Clostridium difficile-associated
diarrhea (CDAD). Vancocin® is also used for the treatment of
enterocolitis caused by Staphylococcus aureus including
methicillin-resistant strains.
According to IMS Health, Vancocin® 125mg and 250mg had combined sales of
approximately $328 million in the U.S. for the twelve months ended
December 31, 2011. Akorn has begun shipping its U.S. Food and Drug
Administration (FDA) approved generic version in both strengths in a 20
capsule pack size.
Source: Akorn, Inc.
LabVantage celebrates customer success with record number of software deployments in FY 2024